CDSCO gives nod to Cipla to conduct study on Paxlovid

Pfizer is also conducting a global study as part of which they have selected 14 different hospitals across India.

366
CDSCO Central Drug Standard Control Organisation
CDSCO

Last Updated on December 31, 2023 by The Health Master

Pharmaceutical major, Cipla has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct local trials on the anti C-19 pill Paxlovid.

In its meeting held this week, the SEC granted approval to the company to conduct bioavailability and bio equivalence (BA/BE) studies.

Cipla will carry study on 44 participants and soon share data with the regulatory authority,” a government official said.

Cipla is the third company to have gone ahead with conducting BA/BE studies for the launch of generic Paxlovid.

Hetero Labs and Optimus pharma are also conducting the same trials.

“While the active pharmaceutical ingredient (API) is ready, the formulation will take time. We are in the process of starting a study to evaluate the safety of the product,” an Optimus executive had earlier told ET.

The companies will conduct BA/BE studies and submit safety data for review to the drug regulator in a few months.

Pfizer is also conducting a global study as part of which they have selected 14 different hospitals across India.

Pfizer has already received emergency use authorisation (EUA) in about 40 countries including Canada, UK and the European Union. China is the latest country to have given conditional approval to Pfizer’s Paxlovid to treat adults with mild to moderate illness and a high risk of developing severe disease.

US drug giant Pfizer had last year announced a deal with MPP, a UN-backed public health organisation, to issue royalty free voluntary licences to manufacture generic versions of Paxlovid, an oral antiviral C-19 medication, in 95 middle and low income countries (LMICs), including India.

IPA to organise 7th Global Pharmaceutical Quality Summit

BIS sets standard for these Medical Devices

The mandatory QR codes on APIs

NPPA fixes retail price of 19 formulations: February 2022

ICMR to conduct Clinical Trial for new drugs regimen for MDR TB

PCB issues directions to Pharma Companies to comply with norms

Police protection sought for Drugs Control Officers

USFDA gives nod to Lupin for sNDA for Solosec

India reports outbreak of H5N1 Bird Flu Virus

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news